- Home
- BLRX vs JSPR Comparison
BLRX vs JSPR Comparison
Compare BLRX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | JSPR |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | Israel | United States |
| Employees | N/A | 22 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 14.9M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLRX | JSPR |
|---|---|---|
| Price | $3.33 | $0.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $19.00 | $15.50 |
| AVG Volume (30 Days) | 28.8K | ★ 705.5K |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.42 |
| 52 Week High | $5.05 | $7.19 |
Technical Indicators
Market Signals| Indicator | BLRX | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 34.37 |
| Support Level | $3.07 | $0.42 |
| Resistance Level | $3.53 | $1.02 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 62.84 | 26.21 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.